

CURRICULUM VITAE

Ourania E. Tsitsilonis

Address: Section of Animal and Human Physiology, Department of Biology, National and Kapodistrian University of Athens (NKUA), Panepistimiopolis, 15784, Ilissia, Athens, Greece
Tel: +30 (210) 7274215; e-mail: rtsitsil@biol.uoa.gr

EDUCATION

1986: B.Sc. Biology, NKUA, Greece

1993: Ph.D. in Biological Sciences (Immunology), NKUA, Greece

1995: M.D. School of Medicine, NKUA, Greece

APPOINTMENTS

1993-1996: Post-doctoral Research Fellow, Department of Biology, NKUA, Greece and Physiologisch-chemisches Institut, University of Tuebingen, Germany (Prof. W. Voelter)

1996-1997: Resident in Histopathology-Cytology, “Saint Savas” Cancer Hospital, Athens, Greece

1998-1999: Obligatory service as general practitioner, Greece

1999-2002: Resident in Biopathology, General Oncology Hospital “Saint Anargiri”, Kifissia and “Saint Savas” Cancer Hospital, Athens, Greece

1996-2002: Senior Investigator, Department of Immunology, “Saint Savas” Cancer Hospital, Greece

2002-2007: Lecturer in Immunobiology, Department of Biology, NKUA, Greece

2007-2014: Assistant Professor of Immunology, Department of Biology, NKUA, Greece

2014-2018: Associate Professor of Immunology, Department of Biology, NKUA, Greece

2018-present: Professor of Immunology, Department of Biology, NKUA, Greece

2015-present: Vice-President of Department of Biology, NKUA, Greece

019-present: Adjunct Professor of Department of Life Sciences (Tumor Immunology), European University Cyprus

MEMBERSHIPS

Athens Medical Association, Hellenic Society of Immunology, Hellenic Society of Microbiology, European Society of Clinical Microbiology and Infectious Diseases, Hellenic Society for Biological Sciences, Hellenic Union of Bioscientists (Board of Directors Member 2005-2006), Hellenic Society of Immuno-Oncology (Founding Member & Secretary General, 2015-present).

TEACHING

2002-present: Lectures and practicals in Immunology, Animal Physiology, Comparative Animal Physiology, History of Biology, and Neurobiology for undergraduate students of the Department of Biology

2002-present: Lectures and practicals in the MSc Programs: “Applications of Biology in Medicine” (Dpt Biology), “Clinical Biochemistry-Molecular Diagnostics” (Dpt Biology), “Modern Trends in the teaching of Biology” (Dpt Biology), “Athens International Master’s Programme in Neurosciences” (Dpt Biology), “Clinical Chemistry” (Dpt Chemistry), “Biotechnology of Enzymes” (Agricultural University of Athens), “Oncology of the Thorax” (School of Medicine, NKUA), “Medical Genetics: Clinical and Laboratory Direction” (School of Medicine, NKUA), “Development of new drugs: research, launch and access” (School of Medicine, NKUA), “Oncology: from Oncogenesis to Therapy” (School of Medicine, University of Crete), “Clinical Trials: Design and Conduct” (School of Medicine, NKUA), “Infectious Diseases-International Medicine: from bench to bedside” (Demokritus University of Thrace).

REVIEWER OF SCIENTIFIC JOURNALS & RESEARCH PROPOSALS

- Reviewer of the Journals: Cancer, Cancer Immunology Immunotherapy, Immunology, Proteomics, Medicinal Chemistry, Journal of Membrane Biology, Advances in Clinical Chemistry, FEBS Journal, Oncotarget, Oncoimmunology, JoV, Expert Opinion on Biological Therapy, BBActa, African Journal of Biotechnology, Journal of Toxicology and Environmental Health, Archives in Dermatology, Hepatobiliary Pancreatic Disease, Human Immunology, BMC Immunology, BMC Physiology, Pharmacologia, Theranostics, etc
- Reviewer of Research Proposals for the General Secretariat for Research and Technology, Hellenic Ministry of Education, the Hellenic Scholarships Foundation (IKY)
- Reviewer of Research Proposals for the Universities of Antwerp and Ghent, Belgium; the University of Sofia and The Bulgarian Academy of Sciences, Bulgaria; Nicosia Research Foundation, Cyprus; the Romanian Academy of Sciences.

RESEARCH GRANTS

SARG-NKUA, The Hellenic Ministry of Education, The General Secretariat for Research and Technology-Hellenic Ministry of Development, The Hellenic Ministry of Health, Empirikeion Foundation, John Latsis Foundation, IKY (IKYDA 2003, 2007, 2010, 2016), NATO-SfP and the EU.

SELECTED PUBLICATIONS (last 10 years)

1. Gavalas NG, Tsiatas M, **Tsitsilonis O**, Politi E, Ioannou K, Ziogas AC, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Terpos E, Antsaklis A, Dimopoulos MA, Bamias A. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. *Br. J. Cancer* 107: 1869-75, 2012.
2. Voutsas IF, Pistamaltzian N, Tsiatas ML, Skopeliti M, Katsila T, Mavrothalassiti E, Spyrou S, Dimopoulos MA, **Tsitsilonis OE**, Bamias A. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin alpha or its immunoactive decapeptide lyse autologous tumor cells in vitro and retard tumor growth in SCID mice. *Eur. J. Cancer* 49:1706-14, 2012.
3. Baxevanis CN, Voutsas IF, **Tsitsilonis OE**. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies. *Immunotherapy* 5:497-511, 2013.
4. Samara P, Kalbacher H, Ioannou K, Radu DL, Livaniou E, Promponas VJ, Voelter W, **Tsitsilonis O**. Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin α (100-109) in sera of mice infected with bacteria. *J. Immunol. Meth.* 395: 54-62, 2013.
5. Ioannou K, Derhovanessian E, Tsakiri E, Samara P, Kalbacher H, Voelter W, Trougakos IP, Pawelec G, **Tsitsilonis OE**. Prothymosin α and a prothymosin α -derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes. *BMC Immunol.* 14: 43-49, 2013.
6. Ioannou K, Cheng KF, Crichlow GV, Birmipilis AI, Lolis EJ, **Tsitsilonis OE**, Al-Abad Y. ISO-66, a novel inhibitor of macrophage migration inhibitory factor, shows efficacy in melanoma and colon cancer models. *Int. J. Oncol.* 45: 1457-68, 2014.
7. Kostopoulos IV, Paterakis G, Papadimitriou K, Pavlidis D, **Tsitsilonis OE**, Papadimitriou SI. Immunophenotypic analysis reveals heterogeneity and common biologic aspects in monoclonal B-cell lymphocytosis. *Genes Chromosomes Cancer* 54: 210-21, 2015.
8. Papaioannou NE, Voutsas IF, Samara P, **Tsitsilonis OE**. A flow cytometric approach for studying alterations in the cytoplasmic concentration of calcium ions in immune cells following stimulation with thymic peptides. *Cell. Immunol.* 302:32-40, 2016.
9. Samara P, Ioannou K, **Tsitsilonis OE**. Prothymosin alpha and immune responses: are we close to potential clinical applications? *Vitam. Horm.* 102:179-207, 2016.
10. Papaioannou NE, Beniata OV, Vitsos P, **Tsitsilonis O**, Samara P. Harnessing the immune system to improve cancer therapy. *Ann. Transl. Med.* 4:261, 2016.
11. Goldeck D, Theeten H, Hassouneh F, Oettinger L, Wistuba-Hamprecht K, Cools N, **Tsitsilonis OE**, Pawelec G. Frequencies of peripheral immune cells in older adults following seasonal influenza vaccination with an adjuvanted vaccine. *Vaccine* 35:4330-4338, 2017.
12. Samara P, Miriagou V, Zachariadis M, Mavrofydi O, Promponas VJ, Dedos SG, Papazafiri P, Kalbacher H, Voelter W, **Tsitsilonis O**. A fragment of the alarmin prothymosin α as a novel biomarker in murine models of bacterial-induced sepsis. *Oncotarget* doi: 10.18632/oncotarget.18149, 2017.
13. Kostopoulos IV, Paterakis G, Pavlidis D, Kastritis E, Terpos E, **Tsitsilonis OE**, Papadimitriou SI. Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis. *Blood Cancer J.* 7:e597, 2017.
14. Cheimonidi C, Samara P, Polychronopoulos P, Tsakiri EN, Nikou T, Myriantopoulos V, Sakellaropoulos T, Zoumpourlis V, Mikros E, Papassideri I, Argyropoulou A, Halabalaki M, Alexopoulos LG, Skaltsounis AL, **Tsitsilonis OE**, Aligiannis NN, Trougakos IP. Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights. *Redox Biol.* 16:169, 2018.
15. Kastritis E, Kostopoulos IV, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M, Kanellias N, Ziogas DC, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Trougakos IP, **Tsitsilonis O**, Dimopoulos MA. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. *Blood Cancer J.* 8:46, 2018.
16. Karachaliou CE, Kalbacher H, Voelter W, **Tsitsilonis OE**, Livaniou E. In vitro immunodetection of prothymosin alpha in normal and pathological conditions. *Curr. Med. Chem.* doi: 10.2174/0929867326666190807145212, 2019.
17. Kastritis E, Dialoupi I, Gavriatopoulou M, Roussou M, Kanellias N, Fotiou D, Ntanasis-Stathopoulos I, Papadopoulou E, Ziogas DC, Stamatelopoulos K, Manios E, Ntalianis A, Eleutherakis-Papaiakovou E, Papanikolaou A, Migkou M, Papanota AM, Gakiopoulou H,

- Psimenou E, Tselegkidi MI, **Tsitsilonis O**, Kostopoulos I, Terpos E, Dimopoulos MA. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide and dexamethasone. *Blood Adv.* 3:3002, 2019.
18. Birmopilis AI, Karachaliou CE, Samara P, Ioannou K, Selemenakis P, Kostopoulos IV, Kavrochorianou N, Kalbacher H, Livaniou E, Haralambous S, Kotsinas A, Farzaneh F, Trougakos IP, Voelter W, Dimopoulos MA, Bamias A, **Tsitsilonis O**. Antitumor reactive T cell responses are enhanced in vivo by DAMP prothymosin alpha and its C-terminal decapeptide. *Cancers (Basel)* doi: 10.3390/cancers1111764, 2019.
 19. Amanatidou AI, Nastou KC, **Tsitsilonis OE**, Iconomidou VA. Visualization and analysis of the interaction network of proteins associated with blood-cell targeting autoimmune diseases. *Biochim Biophys Acta Mol. Basis Dis.* 1866:165714, 2020.
 20. Iliou A, Panagiotakis A, Giannopoulou AF, Benaki D, Kosmopoulou M, Velentzas AD, **Tsitsilonis OE**, Papassideri IS, Voutsinas GE, Konstantakou EG, Gikas E, Mikros E, Stravopodis DJ. Malignancy grade-dependent mapping of metabolic landscapes in human urothelial bladder cancer: identification of novel, diagnostic and druggable biomarkers. *Int. J. Mol. Sci.* 21:18792, 2020.
 21. Kostopoulos IV, Ntanas-Stathopoulos I, Gavriatopoulou M, **Tsitsilonis OE**, Terpos E. Minimal residual disease in Multiple Myeloma: current landscape and future applications with immunotherapeutic approaches. *Front. Oncol.* 10:860, 2020.
 22. **Tsitsilonis OE**, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastritis E, Moutsatsou P, Scorilas A, Sphicopoulos T, Terpos E, Thomaidis N, Tsakris A, Voulgaris N, Daskalaki CC, Evangelakou Z, Fouki C, Gianniou DD, Gumeni S, Kostaki EG, Kostopoulos IV, Manola MS, Orologas-Stavrou N, Panteli C, Papanagnou ED, Rousakis P, Sklirou AD, Smilkou S, Stergiopoulou D, Trougakos IP, Tsiodras S, Sfikakis PP, Dimopoulos MA. Seroprevalence of antibodies against SARS-CoV-2 among the personnel and students of the National and Kapodistrian University of Athens, Greece: a preliminary report. *Life (Basel)* 10:214, 2020.
 23. Papadimitriou K, Tsakirakis N, Malandrakis P, Vitsos P, Metousis A, Orologas-Stavrou N, Ntanas-Stathopoulos I, Kanellias N, Eleutherakis-Papaiakovou E, Pothos P, Fotiou D, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Terpos E, **Tsitsilonis OE**, Kostopoulos IV. Deep phenotyping reveals distinct immune signatures correlating with prognostication, treatment responses, and MRD status in Multiple Myeloma. *Cancers (Basel)* 12:3245, 2020.
 24. Orologas-Stavrou N, Politou M, Rousakis P, Kostopoulos IV, Ntanas-Stathopoulos I, Jahaj E, Tsiligkeridou E, Gavriatopoulou M, Kastritis E, Kotanidou A, Dimopoulos MA, **Tsitsilonis OE**, Terpos E. Peripheral blood immune profiling of convalescent plasma donors reveals alterations in specific immune subpopulations even at 2 months post SARS-CoV-2 infection. *Viruses* 13:26, 2020.
 25. Trougakos IP, Stamatelopoulos K, Terpos E, **Tsitsilonis OE**, Aivalioti E, Paraskevis D, Kastritis E, Pavlakis GN, Dimopoulos MA. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. *J. Biomed. Sci.* 28:9, 2021.
 26. **Tsitsilonis OE**, Paraskevis D, Lianidou E, Terpos E, Akalestos A, Pierros V, Kostaki EG, Kastritis E, Moutsatsou P, Scorilas A, Sphicopoulos T, Thomaidis N, Trougakos IP, Tsakris A, Vourgarris N, Daskalaki CC, Evangelakou Z, Fouki C, Gianniou DD, Gumeni S, Kostopoulos IV, Manola MS, Orologas-Stavrou N, Panteli C, Papanagnou ED, Rousakis P, Sklirou AD, Smilkou S, Stergiopoulou D, Tsiodras S, Dimopoulos MA, Sfikakis PP. SARS-CoV-2 infection is asymptomatic in nearly half of adults with robust anti-spike protein receptor-binding domain antibody response. *Vaccines (Basel)* 9:207, 2021.
 27. Tzounakas VL, Anastasiadi AT, Stefanoni D, Cendali F, Bertolone L, Gamboni F, Dzieciatkowska M, Rousakis P, Vergaki A, Soulikis V, **Tsitsilonis OE**, Stamoulis K, Papassideri IS, Kriebardis ANG, D'Alessandro A, Antonelou MH. β -thalassemia minor is a beneficial determinant of red blood cell storage lesion. *Haematologica* doi: 10.3324/haematol.2020.273946, 2021.
 28. Cheimonidi C, Grivas IN, Sesti F, Kavrochorianou N, Gianniou DD, Taoufik E, Badounas F, Papassideri I, Rizzi F, **Tsitsilonis OE**, Haralambous S, Trougakos IP. Clusterin overexpression in mice exacerbates diabetic phenotypes but suppresses tumor progression in a mouse melanoma model. *Aging (Albany NY)* 13:6485, 2021.
 29. Tsoumani M, Georgoulis A, Nikolaou PE, Kostopoulos IV, Dermintzoglou T, Papatheodorou I, Zoga A, Efentakis P, Konstantinou M, Gikas E, Kostomitsopoulos N, Papapetropoulos A, Lazou A, Skaltsounis AL, Hausenloy DJ, **Tsitsilonis O**, Tseti I, Di Lisa F, Iliodromitis EK, Andreadou I. Acute administration of the olive constituent, oleuropein, combined with ischemic postconditioning increases myocardial protection by modulating oxidative defense. *Free Radic. Biol. Med.* 166:18, 2021.

30. Kostopoulos IV, Orologas-Stavrou N, Rousakis P, Panteli C, Ntanasis-Stathopoulos I, Charitaki I, Korompoki E, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos MA, **Tsitsilonis OE**, Terpos E. Recovery of innate immune cells and persisting alterations in adaptive immunity in the peripheral blood of convalescent plasma donors at eight months post SARS-CoV-2 infection. *Microorganisms* 9:546, 2021.
31. Kostopoulos IV, Eleutherakis-Papaiakovou E, Rousakis P, Ntanasis-Stathopoulos I, Panteli C, Orologas-Stavrou N, Kanellias N, Malandrakis P, Liacos CI, Papaioannou NE, Papanota AM, Migkou M, Fotiou D, Gavriatopoulou M, Angelis NV, Kastritis E, Dimopoulos MA, **Tsitsilonis OE**, Terpos E. Aberrant plasma cell contamination of peripheral blood stem cell autografts, assessed by next-generation flow cytometry, is a negative predictor for deep response post autologous transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. *Cancers (Basel)* 13:4047, 2021.
32. Giannopoulou AF, Velentzas AD, Anagnostopoulos AK, Agalou A, Papandreou NC, Katarachia SA, Koumoundourou DG, Konstantakou EG, Pantazopoulou VI, Delis A, Michailidi MT, Valakos D, Chatzopoulos D, Syntichaki P, Iconomidou VA, **Tsitsilonis OE**, Papassideri IS, Voutsinas GE, Hatzopoulos P, Thanos D, Beis D, Anastasiadou E, Tsangaris GT, Stravopodis DJ. From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. *Cancers (Basel)* 13:2024, 2021.
33. Valiakou V, Eliadis P, Karamichali E, **Tsitsilonis O**, Koskinas J, Georgopoulou U, Foka P. Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment. *Int. J. Mol. Sci.* 22:7961, 2021.
34. Karamitros T, Pogka V, Papadopoulou G, **Tsitsilonis O**, Evangelidou M, Sympardi S, Mentis A. Dual RNA-Seq Enables Full-Genome Assembly of Measles Virus and Characterization of Host-Pathogen Interactions. *Microorganisms* 9:1538, 2021.
35. Kastritis E, Rousakis P, Kostopoulos IV, Gavriatopoulou M, Theodorakakou F, Fotiou D, Dialoupi I, Migkou M, Roussou M, Kanellias N, Tselegkidi MI, Eleutherakis-Papaiakovou E, Papanikolaou A, Gakiopoulou C, Psimenou E, Spyropoulou-Vlachou M, Gatou A, Terpos E, **Tsitsilonis O**, Dimopoulos MA. Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. *Amyloid* 2021 (in press).